• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

LITESPARK-003 Trial Insights: Updates from ESMO 2023

Opinion
Video

An overview of the LITESPARK-003 study of belzutifan from ESMO 2023 and the role of HIF2α inhibitors in renal cell carcinoma (RCC).

This is a video synopsis/summary of a panel discussion involving Sia Daneshmand, MD.

Daneshmand discusses results from the LITESPARK-003 phase 2 trial evaluating belzutifan plus cabozantinib in advanced RCC. Belzutifan is a HIF-2α inhibitor approved for Von Hippel–Lindau disease–associated RCC. The LITESPARK-003 trial had 2 cohorts; cohort 1 was first-line, and cohort 2 was subsequent line therapy.

Cohort 1 included 50 patients with favorable risk, whereas cohort 2 had 51 patients with intermediate/poor risk. At a median follow-up of 2 years in cohort 1 and 40 months in cohort 2, median overall survival was not reached in cohort 1 and was 26.7 months in cohort 2. The combination showed antitumor activity and was fairly well tolerated, with no treatment-related deaths.

Daneshmand notes that although these are exciting results, determining the optimal place for belzutifan combinations within the evolving RCC treatment landscape of multiple combinations therapies remains to be seen. Nonetheless, having additional active targeted therapy options is positive.

Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.

Related Videos
Screenshot of Stephen Freedland, MD, during a video interview
"Integrating New PAH Therapies into Clinical Practice"
"Clinical Evidence for Emerging PAH Therapies"
Screenshot of Angela Jia, MD, PhD, during a video interview
Screenshot of Mary Dunn, MSN, NP-C, OCN, RN, during a video interview
Screenshot of Yuzhi Wang, MD, in a video interview
Dr Chris Pagnani
Video 13 - "Individualized Therapy for Specific Infections Associated with Bronchiectasis"
Michael Morse, MD, Duke University Cancer Center
Amit Singal, MD, UT Southwestern Medical Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.